A federal jury has convicted the founders of Done, one of the fastest-growing telehealth companies in the stimulant-prescribing space, for orchestrating one of the largest Adderall distribution and fraud schemes in U.S. history. More than 40 million stimulant pills, over $100 million in revenue, and a business model engineered around speed, volume, and automated prescribing — all built with no real clinical guardrails.In this episode, host Alex Yarijanian breaks down not only what happened, but what this case means for the entire digital health ecosystem, especially behavioral health and companies prescribing controlled substances. When a company like Done collapses — and its founders now face up to 20 years in federal prison — it doesn’t just take itself down. It drags trust, access, and payer willingness down with it.Alex outlines how this case will reshape:Payer contracting and credentialingPrescribing oversight and compliance expectationsTrust in telehealth platformsThe future of value-based behavioral healthWhy incentives — good or bad — always scaleAnd most importantly, he explains why value-based care is the antidote to the shortcuts and misaligned incentives that fueled this scandal.If you’re building, funding, regulating, or partnering with telehealth organizations, this is a must-listen.Takeaways:The case of the telehealth startup highlights the critical importance of clinical oversight in health services. Payers are likely to impose stricter regulations on telehealth providers following recent fraudulent activities. Building a sustainable healthcare model requires prioritizing patient interests over profit maximization strategies. The future of digital health will hinge on trust, necessitating alignment between clinical and business models.